KRAS and neoplasm: Recent data showed that combining the MDM2-p53 protein-protein interaction inhibitor SAR405838 and the MEK inhibitor pimasertib resulted in synergic anti-tumor activity in several K-RAS, N-RAS and B-RAF mutant tumor models [44].